Regorafenib
- Generic Name
- Regorafenib
- Brand Names
- Stivarga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H15ClF4N4O3
- CAS Number
- 755037-03-7
- Unique Ingredient Identifier
- 24T2A1DOYB
- Background
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
- Indication
Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresecta...
- Associated Conditions
- Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Gastrointestinal Stromal Tumor (GIST), Locally advanced Gastrointestinal stromal tumor, Unresectable Gastrointestinal stromal tumor
- Associated Therapies
- -
Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Wei Zhang
- Target Recruit Count
- 30
- Registration Number
- NCT05818267
- Locations
- 🇨🇳
Department of Colorectal Surgery in Changhai Hospital, Shanghai, Shanghai, China
Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-04-13
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- WenBo Guo
- Target Recruit Count
- 192
- Registration Number
- NCT05811481
- Locations
- 🇨🇳
FirstSunYetSen, Guangzhou, Guangdong, China
Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 126
- Registration Number
- NCT05794971
- Locations
- 🇨🇳
Bo Zhang, Guangdong, Guangzhou, China
Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2024-02-23
- Target Recruit Count
- 46
- Registration Number
- NCT05770882
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05717738
- Locations
- 🇨🇳
Optical Valley branch of Tongji hospital, Wuhan, Hubei, China
🇨🇳The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
🇨🇳Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Wan-Guang Zhang
- Target Recruit Count
- 300
- Registration Number
- NCT05713994
- Locations
- 🇨🇳
TongjiHospital, Wuhan, Hubei, China
🇨🇳The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 63
- Registration Number
- NCT05672316
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours
- Conditions
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2022-12-09
- Target Recruit Count
- 30
- Registration Number
- NCT05644392
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2022-12-09
- Target Recruit Count
- 30
- Registration Number
- NCT05644379
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
- Conditions
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 94
- Registration Number
- NCT05600309
- Locations
- 🇨🇳
Hainan General Hospital ( Site 1177), Haikou, Hainan, China
🇨🇳Fujian Province Cancer Hospital ( Site 1178), Fuzhou, Fujian, China
🇨🇳The Sixth Affiliated Hospital of Sun Yat-sen University ( Site 1159), Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.